公开(公告)号：KR100394083B1

公开(公告)日：2003-08-06

申请号：KR1020000073122

申请日：2000-12-04

Applicant: 한국과학기술연구원 ,  한국과학기술원 ,  한국화학연구원 ,  학교법인 성신학원

Inventor： 고훈영 ,  최경일 ,  조용서 ,  배애님 ,  공재양 ,  정대영 ,  정선호 ,  정지영 ,  이희윤

IPC: C07D413/14

CPC classification number: C07D413/04 ,  C07D261/08

Abstract: The present invention relates to 4,5-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 and D4 receptors represented by the following Formula (1), and its preparation method through reductive amination reaction in the presence of reducing agent,wherein R1, R2, X and n are the same as defined in the specification.

Abstract translation: 本发明涉及对下式（1）所示的多巴胺D3和D4受体具有选择性生物活性的4,5-二氢异恶唑烷基哌嗪衍生物及其在还原剂存在下通过还原胺化反应的制备方法，其中R1，R2， X和n与说明书中定义的相同。

公开(公告)号：KR1020080094475A

公开(公告)日：2008-10-23

申请号：KR1020070038962

申请日：2007-04-20

Applicant: 한국화학연구원

Inventor： 공재양 ,  박우규 ,  조희영 ,  정대영 ,  최길돈 ,  배애님

IPC: A61K31/551 ,  A61K31/435 ,  A61K31/40 ,  A61P25/18

CPC classification number: A61K31/4468 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/40 ,  A61K31/495 ,  A61K31/496 ,  A61K31/551

Abstract: 12 compounds are provided to show excellent binding affinity to serotonin 5-HT2A receptor, thereby being usefully used as a prophylactic or a therapeutic agent of central nervous system diseases such as anxiety, hypochondria, stroke, neurosis, psychosis, schizophrenia, suicidal tendency, Alzheimer's disease, Parkinson's disease, Huntington's chorea, sleep disorders, appetite disorders, cocaine, withdrawal symptoms caused by drug abuse, and migraine. A pharmaceutical composition for preventing and treating central nervous system diseases related to serotonin 5-HT2A receptor comprises a compound selected from the group consisting of naphthalene-2-sulfonic acid methyl-(1-methyl-piperidin-4-yl)-amide, 1-(5-bromo-2-methoxy-benzenesulfonyl)-4-(2-thiopen-2-yl-ethyl)-piperazine, 1-(1-benzyl-piperidin-4-yl)-3-(4-trifluoromethylsulfanyl-phenyl)-urea, 8-[4-(3-phenyl-aryl)-piperazin-1-sulfonyl]-quinoline, 1-(1-benzyl-pyrrolidin-3-yl)-3-(4-trifluoromethylsulfanyl-phenyl)-urea, 1-(4-butoxy-benzenesulfonyl)-4-methyl-[1,4]diazepane, 1-[4-(3,4-dimethyl-phenyl)-piperazin-1-yl]-3-phenoxy]-propan-2-one, biphenyl-4-sulfonic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide, 1-(2,5-dichloro-benzenesulfonyl)-4-penethyl-piperazine, 1-penethyl-4-(toluene-4-sulfonyl)-piperazine, 1-(2-fluoro-5-methyl-benzenesulfonyl)-4-penethyl-piperazine, and 1-(4-bromo-benzenesulfonyl)-4-penethyl-piperazine or a pharmaceutically acceptable salt thereof. The composition is formulated into tablet, capsule, solution, syrup, suspension and injection.

Abstract translation: 提供了12种化合物以显示与5-羟色胺5-HT2A受体的极好的结合亲和力，从而有效地用作中枢神经系统疾病如焦虑症，hypochondria，中风，神经症，精神病，精神分裂症，自杀倾向，阿尔茨海默氏症的预防或治疗剂 疾病，帕金森病，亨廷顿舞蹈病，睡眠障碍，食欲障碍，可卡因，药物滥用引起的戒断症状和偏头痛。 用于预防和治疗与5-羟色胺5-HT 2A受体相关的中枢神经系统疾病的药物组合物包括选自萘-2-磺酸甲基 - （1-甲基 - 哌啶-4-基） - 酰胺，1 - （5-溴-2-甲氧基 - 苯磺酰基）-4-（2-噻吩-2-基 - 乙基） - 哌嗪，1-（1-苄基 - 哌啶-4-基）-3-（4-三氟甲硫基 - 苯基） - 脲，8- [4-（3-苯基 - 芳基） - 哌嗪-1-磺酰基] - 喹啉，1-（1-苄基 - 吡咯烷-3-基）-3-（4-三氟甲硫基 - 苯基） - 脲，1-（4-丁氧基苯磺酰基）-4-甲基 - [1,4]二氮杂环庚烷，1- [4-（3,4-二甲基 - 苯基） - 哌嗪-1-基] -3-苯氧基] - 丙-2-酮，联苯-4-磺酸[2-（1-甲基 - 吡咯烷-2-基） - 乙基] - 酰胺，1-（2,5-二氯 - 苯磺酰基）-4-苯乙基 - 哌嗪 ，1-苯乙基-4-（甲苯-4-磺酰基） - 哌嗪，1-（2-氟-5-甲基 - 苯磺酰基）-4-辛基 - 哌嗪和1-（4-溴 - 苯磺酰基）-4- 哌嗪或其药学上可接受的盐。 将组合物配制成片剂，胶囊，溶液，糖浆，悬浮液和注射剂。

公开(公告)号：KR1020020043413A

公开(公告)日：2002-06-10

申请号：KR1020000073122

申请日：2000-12-04

Applicant: 한국과학기술연구원 ,  한국과학기술원 ,  한국화학연구원 ,  학교법인 성신학원

Inventor： 고훈영 ,  최경일 ,  조용서 ,  배애님 ,  공재양 ,  정대영 ,  정선호 ,  정지영 ,  이희윤

IPC: C07D413/14

CPC classification number: C07D413/04 ,  C07D261/08

Abstract: PURPOSE: Provided are novel 4,5-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity to dopamine D3 and D4 receptors, and their preparation method by reductive amination in the presence of reductant. CONSTITUTION: 4,5-dihydroisoxazolylalkylpiperazine derivative is represented by the formula(1), wherein R1, R2, R3, R4 and R5 are identical or different from each other, and represents individually hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 alkoxy group, C2-C6 alkenyl group, hydroxy group , hydroxymethyl group, aryl group, heteroaryl group, amino group, C1-C6 alkyl amino group, carbonyl group, C3-C8 cycloalkyl group, or C3-C8 heterocyclic group; R6 represents hydrogen atom, halogen atom, alkyl group, C1-C6 alkoxy group, aryl group, pyridyl group, heterocyclic group or pyrimidyl group; X represents CH or nitrogen atom; and n is 3 or 4.

Abstract translation: 目的：提供对多巴胺D3和D4受体具有选择性生物活性的新型4,5-二氢异恶唑烷基哌嗪衍生物及其在还原剂存在下还原胺化的制备方法。 构成：4,5-二氢异恶唑基烷基哌嗪衍生物由式（1）表示，其中R 1，R 2，R 3，R 4和R 5彼此相同或不同，并且表示单独的氢原子，卤素原子，C1-C6烷基， C1-C6烷氧基，C2-C6烯基，羟基，羟甲基，芳基，杂芳基，氨基，C1-C6烷基氨基，羰基，C3-C8环烷基或C3-C8杂环基; R6表示氢原子，卤素原子，烷基，C1-C6烷氧基，芳基，吡啶基，杂环基或嘧啶基; X表示CH或氮原子; n为3或4。

公开(公告)号：KR100890633B1

公开(公告)日：2009-03-27

申请号：KR1020070038962

申请日：2007-04-20

Applicant: 한국화학연구원

Inventor： 공재양 ,  박우규 ,  조희영 ,  정대영 ,  최길돈 ,  배애님

IPC: A61K31/551 ,  A61K31/435 ,  A61K31/40 ,  A61P25/18

Abstract: 본 발명은 세로토닌 수용체에 대한 친화력을 갖는 화합물에 관한 것으로, 더욱 상세하게는 세로토닌 5-HT
2A
수용체에 대한 길항활성이 우수하므로 중추신경계 질환 예를 들면 불안증(anxiety), 우울증, 발작, 강박노이로제, 정신병(psychosis), 정신분열증, 자살 성향(suicidal tendency), 알츠하이머형 치매, 파킨슨병, 헌팅턴 무도병(Huntington's chorea), 수면 장애(sleep disorders), 식욕 장애(appetite disorders), 약물남용에 의한 금단 증상, 및 편두통 등의 치료 및 예방제로서 유용한 화합물에 관한 것이다.
세로토닌(5-HT), 5-HT2A 수용체, 우울증, 정신분열증

公开(公告)号：KR100868353B1

公开(公告)日：2008-11-12

申请号：KR1020070022845

申请日：2007-03-08

Applicant: 한국화학연구원

Inventor： 공재양 ,  박우규 ,  조희영 ,  정대영 ,  최길돈 ,  고훈영 ,  배애님 ,  조용서 ,  차주환 ,  추현아 ,  채상은 ,  김상희 ,  이희윤

IPC: C07D401/06 ,  A61K31/437

CPC classification number: C07D403/06

Abstract: 본 발명은 신규 피페라지닐프로필피라졸 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물에 관한 것이다. 본 발명의 신규 피페라지닐프로필피라졸 유도체는 도파민 D
4 수용체 친화력이 우수하고, 아포몰핀(Apomorphine)으로 유도된 마우스의 정신병적 행동 (Cage climbing, 철망 기어오르기)을 효과적으로 억제하였을 뿐만 아니라 마우스 로타로드 (rotarod) 시험에서 비교적 약한 부작용을 나타내므로, 중추신경계 질환 구체적으로는 정신분열증, 주의력결핍 과잉행동장애, 우울증, 스트레스성 질환, 공황장애, 공포증, 강박장애, 외상후 스트레스장애, 인식장애, 알츠하이머병, 파킨슨병, 불안증, 망상분열증, 열광증, 경련장애, 인격장애, 편두통, 약물중독, 알코올 중독, 비만, 섭식 장애, 수면장애 등의 치료 및 예방제로 유용하다.
피라졸, 피페라진, 도파민 D4 수용체, 중추신경계 질환, 정신분열증

公开(公告)号：KR1020080082250A

公开(公告)日：2008-09-11

申请号：KR1020070022845

申请日：2007-03-08

Applicant: 한국화학연구원

Inventor： 공재양 ,  박우규 ,  조희영 ,  정대영 ,  최길돈 ,  고훈영 ,  배애님 ,  조용서 ,  차주환 ,  추현아 ,  채상은 ,  김상희 ,  이희윤

IPC: C07D401/06 ,  A61K31/437

CPC classification number: C07D403/06

Abstract: A piperazinyl-propyl-pyrazole derivative is provided to show excellent dopamine D4 affinity, inhibit the psychotic action of a mouse induced by apomorphine and exhibit relatively weak side effect at a mouse rotarod test, thereby being effectively used as a therapeutic and prophylactic agent of central nervous system diseases. A piperazinyl-propyl-pyrazole derivative is represented by a formula(1). In the formula(1), R^1 is C1-10 alkyl, or substituted or unsubstituted aryl or heteroaryl; one of R^2 or R^3 is H, and the other one of R^2 or and R^3 is C1-10 alkyl, benzyl, or substituted or unsubstituted aryl or heteroaryl; each R^4, R^5, R^6, and R^7 is independently H or C1-10 alkyl; each R^8, R^9, R^10, R^11 and R^12 is independently H, halogen, C1-10 alkyl, C1-C10 alkoxy, bis(substituted or unsubstituted aryl)alkylene, benzyl, nitro, hydroxy, cyano, amino, mono- or di-alkylamino, alkylcarbonylamino, aminosulfonyl, mono- or di-alkylaminosulfonyl, alkylcarbonyl, or alkyloxycarbonyl; and a dotted line is a single-bonded line or a double bond, wherein the aromaticity of a pyrazole-ring should be maintained, the aryl is phenyl, the heteroaryl is thiophenyl or pyridyl, and the substituted aryl or heteroaryl is an aryl or a heteroaryl substituted with one to three substituent(s) selected from the group consisting of halogen, nitro, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, and C1-10 haloalkoxy. A method for preparing the piperazinyl-propyl-pyrazole derivative comprises a step of subjecting a pyrazole aldehyde derivative represented by a formula(2) and a piperazine derivative represented by a formula(3) to a reductive amination reaction. A pharmaceutical composition for treating central nervous system diseases comprise the compound of the formula(1).

Abstract translation: 提供哌嗪基 - 丙基 - 吡唑衍生物以显示出优异的多巴胺D4亲和力，抑制阿扑吗啡诱导的小鼠的精神病作用，并且在小鼠旋转试验中显示相对较弱的副作用，从而有效地用作中枢的治疗和预防剂 神经系统疾病 哌嗪基 - 丙基 - 吡唑衍生物由式（1）表示。 在式（1）中，R 1是C 1-10烷基或取代或未取代的芳基或杂芳基; R 2或R 9中​​的一个为H，R 2和R 3中的另一个为C 1-10烷基，苄基或取代或未取代的芳基或杂芳基; 每个R 4，R 5，R 6和R 9独立地是H或C 1-10烷基; 每个R 8，R 9，R 10，R 11和R 12独立地是H，卤素，C 1-10烷基，C 1 -C 10烷氧基，双（取代或未取代的芳基）亚烷基，苄基，硝基，羟基 氰基，氨基，一或二烷基氨基，烷基羰基氨基，氨基磺酰基，一或二烷基氨基磺酰基，烷基羰基或烷氧基羰基; 并且虚线是单键或双键，其中应保持吡唑环的芳香性，芳基为苯基，杂芳基为噻吩基或吡啶基，取代的芳基或杂芳基为芳基或 被一至三个选自卤素，硝基，C 1-10烷基，C 1-10烷氧基，C 1-10卤代烷基和C 1-10卤代烷氧基的取代基取代的杂芳基。 制备哌嗪基 - 丙基 - 吡唑衍生物的方法包括将由式（2）表示的吡唑醛衍生物和由式（3）表示的哌嗪衍生物进行还原胺化反应的步骤。 用于治疗中枢神经系统疾病的药物组合物包含式（1）的化合物。

公开(公告)号：KR100394086B1

公开(公告)日：2003-08-06

申请号：KR1020000073121

申请日：2000-12-04

Applicant: 한국과학기술연구원 ,  한국과학기술원 ,  한국화학연구원

Inventor： 고훈영 ,  최경일 ,  조용서 ,  배애님 ,  강경호 ,  차미영 ,  공재양 ,  정대영 ,  이희윤

IPC: C07D413/14

CPC classification number: C07D413/04 ,  C07D261/08 ,  C07D413/14

Abstract: The present invention relates to a novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptors represented by the following formula (1), and its preparation method through reductive amination reaction in the presence of reducing agent, wherein R1, R2, R3, R4, R5, R6, X and n are the same as defined in the specification.

Abstract translation: 本发明涉及对下式（1）所示的多巴胺D3或D4受体具有选择性生物活性的新型异恶唑烷基哌嗪衍生物及其在还原剂存在下通过还原胺化反应的制备方法，其中R1，R2，R3， R4，R5，R6，X和n与说明书中的定义相同。

公开(公告)号：KR1020020043918A

公开(公告)日：2002-06-12

申请号：KR1020000073121

申请日：2000-12-04

Applicant: 한국과학기술연구원 ,  한국과학기술원 ,  한국화학연구원

Inventor： 고훈영 ,  최경일 ,  조용서 ,  배애님 ,  강경호 ,  차미영 ,  공재양 ,  정대영 ,  이희윤

IPC: C07D413/14

CPC classification number: C07D413/04 ,  C07D261/08 ,  C07D413/14

Abstract: PURPOSE: Provided are novel isoxazolylalkylpiperazine derivatives having selective activity for dopamine D3 and D4 receptor represented by the formula(1) and their manufacturing method by reductive amination in the presence of a reductant. The derivatives and their pharmaceutically acceptable salts are useful in the treatment of mental illness. CONSTITUTION: The novel isoxazolylalkylpiperazine derivative of the formula(1) is prepared by reacting amine compound represented by the chemical formula(2) with aldehyde compound shown in the chemical formula(3) in the presence of a reductant selected from NaBH(OAc)3, NaBH3CN and NaBH4 in a reductive amination reaction. In the formulae, R1,R2,R3,R4, and R5 are same or different each other and are hydrogen atom, halogen atom, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, hydroxy, hydroxymethyl, aryl, heteroaryl, amino group, C1-C6 alkylamino, carbonyl, C3-C8 cycloalkyl, or C3-C8 heterocyclic group; R6 is hydrogen atom, halogen atom, alkyl, C1-C6 alkoxy, aryl, pyridyl, heterocyclic, pyrimidyl group; X is CH or nitrogen atom; and n is 3 or 4.

Abstract translation: 目的：提供具有式（1）表示的多巴胺D3和D4受体选择性活性的新型异恶唑基烷基哌嗪衍生物及其制备方法，在还原胺存在下还原胺化。 衍生物及其药学上可接受的盐可用于治疗精神疾病。 构成：式（1）的新型异恶唑基烷基哌嗪衍生物通过使化学式（2）表示的胺化合物与化学式（3）所示的醛化合物在选自NaBH（OAc）3的还原剂存在下反应来制备 ，NaBH 3 CN和NaBH 4在还原胺化反应中。 在式中，R 1，R 2，R 3，R 4和R 5相同或不同，为氢原子，卤原子，C 1 -C 6烷基，C 1 -C 6烷氧基，C 2 -C 6烯基，羟基，羟甲基，芳基，杂芳基 ，氨基，C1-C6烷基氨基，羰基，C3-C8环烷基或C3-C8杂环基; R6是氢原子，卤素原子，烷基，C1-C6烷氧基，芳基，吡啶基，杂环基，嘧啶基; X是CH或氮原子; n为3或4。